CRC Research Update — October 20, 2026
Today's colorectal cancer research highlights
lynch-syndrome
A collection of 50 issues
Colonoscopy screening shows differential benefit in Lynch syndrome by gene
Skip to content
The CRC Digest
▪ SCREENING
Colonoscopy screening shows differential benefit in Lynch syndrome by gene
More frequent colonoscopy screenings resulting in an increased number of adenomas detected effectively reduces CRC risk in those with a pathogenic variant in MSH2, but MLH1 carriers did not experience the same benefit;
CRC Research Update — October 17, 2026
Today's colorectal cancer research highlights
Colorectal neoplasia detected at young age in Li-Fraumeni syndrome surveillance
Skip to content
The CRC Digest
▪ SCREENING
Colorectal neoplasia detected at young age in Li-Fraumeni syndrome surveillance
In seven women with Li-Fraumeni syndrome, colorectal neoplasia was detected in five patients at a median age of 32.5 years, including one colorectal cancer at age 32 and three advanced adenomas; four
CRC Research Update — October 12, 2026
Today's colorectal cancer research highlights
Colon cancer diagnosed in 41-year-old woman with mosaic NF1 variant
Skip to content
The CRC Digest
◇ RESEARCH
Colon cancer diagnosed in 41-year-old woman with mosaic NF1 variant
A case report describes a 41-year-old woman with a mosaic monoallelic germline pathogenic NF1 variant who developed colon cancer, highlighting the underreported relationship between NF1 variation and colorectal cancer risk. (Explor Neurosci)
This
CRC Research Update — October 05, 2026
Today's colorectal cancer research highlights
CRC Research Update — September 15, 2026
Today's colorectal cancer research highlights
CRC Research Update — September 12, 2026
Today's colorectal cancer research highlights
39-year-old proband with Lynch syndrome shows discordant tumor testing
Skip to content
The CRC Digest
◇ RESEARCH
39-year-old proband with Lynch syndrome shows discordant tumor testing
A 39-year-old man with colorectal cancer and family history fulfilling Amsterdam criteria carried the germline MLH1 c.931A>G variant, with tumors showing MSI-H status despite retained MMR protein expression. (Clinical Case Reports)